A phase III, dose-response evaluation of the efficacy and safety of Clonicel (clonidine HCl [hydrochloride] sustained release) vs. placebo in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)

Trial Profile

A phase III, dose-response evaluation of the efficacy and safety of Clonicel (clonidine HCl [hydrochloride] sustained release) vs. placebo in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2010

At a glance

  • Drugs Clonidine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Addrenex Pharmaceuticals
  • Most Recent Events

    • 04 Oct 2010 The US FDA has approved clonidine extended-release tablets based on results from this and another (32491) trial, according to a Shionogi Pharmaceuticals media release.
    • 11 Sep 2008 Results reported in a Sciele Pharma media release.
    • 11 Aug 2008 Status change from in progress, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top